← Back to Clinical Trials
Recruiting NCT06036238

NCT06036238 The Outreach and Prevention at ALcohol Venues in East Africa Study (OPAL-East Africa- Aim 2) (OPAL-Aim 2)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06036238
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition HIV/AIDS
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2024-05-17
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Healthy Living Intervention (HLI)Standard of Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2024-05-17 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will evaluate the effect of a brief alcohol counseling intervention on PrEP and PEP adherence among adults with heavy alcohol use at high risk for HIV, while gaining insights into the facilitators, barriers, and cost-effectiveness of this approach.

Eligibility Criteria

Inclusion Criteria: * Adult (≥18 years) * HIV-uninfected (by rapid HIV antibody test) * AUDIT-C score of \>=4 for men and \>=3 for women * Attending a clinical visit for initiation of biomedical HIV prevention with oral or injectable PrEP or oral PEP (or the dapivirine vaginal ring, if available) * Has access to a mobile phone Exclusion Criteria: * Ineligible for PrEP based on MoH guidelines * Intention to move away from the study community in the coming year * Gross inebriation or inability to provide informed consent

Contact & Investigator

Central Contact

Kara Marson, MPH

✉ kara.marson@ucsf.edu

📞 650-346-5774

Principal Investigator

Gabriel Chamie, MD, MPH

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT06036238 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying HIV/AIDS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06036238 currently recruiting?

Yes, NCT06036238 is actively recruiting participants. Contact the research team at kara.marson@ucsf.edu for enrollment information.

Where is the NCT06036238 trial being conducted?

This trial is being conducted at Mbita, Kenya, Mbarara, Uganda.

Who is sponsoring the NCT06036238 clinical trial?

NCT06036238 is sponsored by University of California, San Francisco. The principal investigator is Gabriel Chamie, MD, MPH at University of California, San Francisco. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology